Inventor
BUROVA ELENA
US18 patents
⚠️ This page may combine multiple inventors who share the name “BUROVA ELENA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
17 patentsUS9987500B2Jun 5, 2018
Human antibodies to PD-1
REGENERON PHARMA126 citations99
US10358495B2Jul 23, 2019
Anti-LAG3 antibodies and uses thereof
REGENERON PHARMA47 citations96
US9938345B2Apr 10, 2018
Human antibodies to PD-L1
REGENERON PHARMA37 citations94
US10390522B2Aug 27, 2019
Non-human animals having a humanized programmed cell death 1 gene
REGENERON PHARMA6 citations84
US9968674B2May 15, 2018
Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody
REGENERON PHARMA10 citations84
US9913461B2Mar 13, 2018
Genetically modified mouse whose genome comprises a humanized CD274 gene
REGENERON PHARMA4 citations83
US10737113B2Aug 11, 2020
Human antibodies to PD-1
REGENERON PHARMA2 citations73
US11692032B2Jul 4, 2023
Anti-LAG3 antibodies and uses thereof
REGENERON PHARMA3 citations72
US11102961B2Aug 31, 2021
Non-human animals having a humanized lymphocyte-activation gene 3
REGENERON PHARMA1 citations72
US10881086B2Jan 5, 2021
Genetically modified mouse whose genome comprises a humanized CD274 gene
REGENERON PHARMA2 citations72
US10844137B2Nov 24, 2020
Anti-CTLA-4 antibodies and uses thereof
REGENERON PHARMA2 citations72
US10306874B2Jun 4, 2019
Non-human animals having a humanized lymphocyte-activation gene 3
REGENERON PHARMA4 citations72
US12096754B2Sep 24, 2024
Non-human animals having a humanized lymphocyte-activation gene 3
REGENERON PHARMA0 citations62
US12089575B2Sep 17, 2024
Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins
REGENERON PHARMA0 citations62
US12024570B2Jul 2, 2024
Anti-CTLA-4 antibodies and uses thereof
REGENERON PHARMA0 citations62
US11684050B2Jun 27, 2023
Non-human animals having a humanized programmed cell death 1 gene
REGENERON PHARMA1 citations62
US10532096B2Jan 14, 2020
Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
REGENERON PHARMA0 citations52